Femara® Improves Cancer-free Survival in Early Breast Cancer
According to the results of a clinical trial published in the Journal of Clinical Oncology, post-surgery treatment of early breast cancer with the aromatase inhibitor Femara® (letrozole) results in better cancer-free survival than treatment with tamoxifen. For more information, click here.